A double blind cross-over comparison of bunitrolol and placebo in the treatment of angina pectoris.

In 20 patients with stable angina pectoris, o-[3-(tert.-butylamino)-2-hydroxypropoxy]-benzonitrile (bunitrolol) was compared with placebo in a double blind cross-over trial, with monthly treatment periods. There was no difference in the subjective condition of the patient. The bunitrolol treated patients showed a significantly better work capacity (P less than 0.05) and pressure-rate product (P less than 0.01) in the exercise tests. No significant difference could be found in the ST-segment changes. The bunitrolol patients showed a significant reduction in heart rate at rest (P less than 0.01); a significant difference in blood pressure was not found. Bunitrolol is an effective beta-adrenergic blocker, without side-effects in this trial.